F
Facile Therapeutics
Facile Therapeutics – Breaking the devastating cycle of C diff recurrence
About Facile Therapeutics
Facile Therapeutics is a biotechnology company focused on developing innovative treatments for recurrent Clostridium difficile infections (CDI). The company operates in the healthcare and pharmaceutical market, primarily serving patients suffering from debilitating and life-threatening infections of the colon caused by Clostridium difficile. Facile Therapeutics' core product is Ebselen, an anti-toxin drug that has shown a favorable safety profile in humans and aims to reduce the recurrence rates of CDI. The business model revolves around clinical trials and securing funding from organizations such as CARB-X, which has awarded Facile Therapeutics up to $1.25 million, with the potential for an additional $17 million upon achieving certain development milestones. The company generates revenue through these grants and potential future sales of their therapeutic solutions once approved.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Belmont, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CARB-X
Series A1 investor entered at this stage
Berkeley SkyDeck Accelerator
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Facile Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Facile Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.